193 related articles for article (PubMed ID: 11912131)
1. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Holen I; Croucher PI; Hamdy FC; Eaton CL
Cancer Res; 2002 Mar; 62(6):1619-23. PubMed ID: 11912131
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
3. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
[TBL] [Abstract][Full Text] [Related]
9. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
10. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
11. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
13. Expression and functional activity of osteoprotegerin in human malignant gliomas.
Naumann U; Wick W; Beschorner R; Meyermann R; Weller M
Acta Neuropathol; 2004 Jan; 107(1):17-22. PubMed ID: 14504888
[TBL] [Abstract][Full Text] [Related]
14. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
Sanlioglu AD; Koksal IT; Karacay B; Baykara M; Luleci G; Sanlioglu S
Cancer Gene Ther; 2006 Jan; 13(1):21-31. PubMed ID: 16052230
[TBL] [Abstract][Full Text] [Related]
17. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
[TBL] [Abstract][Full Text] [Related]
18. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
[TBL] [Abstract][Full Text] [Related]
19. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
20. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
